Hedia, a Copenhagen, Denmark-based digital therapeutics company within diabetes, raised €3M in Seed extension funding.
The round was supported by existing shareholders and business angels.
The company intends to use the funds to expand its growth strategy and digital health product roadmap, continue to scale their Hedia Diabetes Assistant (HDA), as well as launching the Glooko- integrated holistic diabetes management solution later in the year. Furthermore, Hedia will leverage its competencies in developing smart AI-enabled algorithms and Software-as-a-Medical Device (SaMD) solutions together with strategic partners within chronic metabolic diseases.
Led by newly announced CEO Lars Lund, Hedia is a digital therapeutics company within diabetes, committed to help people with insulin-dependent diabetes gain control of their condition. The solution is today available in 11 countries. Based on habits of the individual person with diabetes and personalized input, its diabetes app generates insulin recommendations by taking many aspects of diabetes management into account – such as recording blood glucose readings, keeping track of active insulin, measuring carbs, calculating an insulin dosage, keeping track of activity and recording blood ketones.
FinSMEs
27/02/2024